#Japan #Singapore #Tokyo #STEMCELL #Tissue Banking

StemCell Innovations Expands in Southeast Asia

StemCell Research Institute has made a significant advancement in its mission to expand its cell banking operations in Southeast Asia by establishing a highly advanced Cell Processing Center and Cell Cryopreservation Center in Singapore. Known as STEMCELL INNOVATIONS PTE. LTD., this center is equipped with cutting-edge technology designed to meet the increasing demand for stem cell therapies in one of the fastest-growing markets in the region.

Background of Southeast Asian Expansion

The demand for umbilical cord blood banking in Southeast Asia is projected to see remarkable growth, with the market size expected to surge from approximately 316 million USD in 2024 to around 1.09 billion USD by 2032, representing an average annual growth rate of 16.8%. This growth is driven by several factors, including heightened interest in stem cell treatments, increased awareness of preventive healthcare, and the expansion of the middle class due to rising income levels, along with continued improvements in medical infrastructure.

With a commanding 99% market share in Japan, StemCell Research Institute aims to leverage its extensive experience in the local market as it ventures into Southeast Asia. Singapore has been identified as the strategic core for the company's expansion in the region, boasting advanced medical infrastructure, a stable regulatory environment, and its position as an international healthcare hub. Future plans include extending cell banking services into neighboring countries such as Indonesia and Vietnam as part of their growth strategy.

Overview of the Cell Processing and Cryopreservation Center

The newly constructed facility is located within the Mapletree Hi-Tech Park, a Green Mark certified building in the Kallang district, spanning approximately 450 square meters. This area is recognized as a hub for innovative companies, including many Japanese enterprises, creating a synergistic environment for research and development in advanced medical fields.

The Cell Processing and Cryopreservation Center has been established based on the rigorous quality management systems perfected in Japan. Key features of the facility include:

• - ISO-compliant Clean Rooms: These rooms are designed to ensure stringent control over particles and microorganisms, adhering to high standards of cleanliness essential for cell processing.
• - 24/7 Monitoring Systems: Essential parameters such as temperature, humidity, and liquid nitrogen levels are continuously monitored to ensure optimal storage conditions.
• - Advanced Monitoring Technology: The facility implements SMARTDAC+® for equipment and environmental monitoring, enhancing data management and traceability.
• - Business Continuity Planning (BCP): The design incorporates self-power generation capabilities, electrical backups, and fire safety measures to mitigate risk effectively.

While the project is expected to uplift the company’s operational capabilities, it is anticipated to have a minor impact on overall financial performance.

Company Profile

StemCell Research Institute operates under the corporate slogan, “New Life, New Medical Choices,” leveraging a strong network with obstetric and gynecological facilities. The company focuses on the development of cell banking services derived from perinatal tissues such as umbilical cords and cord blood, in addition to innovating new treatment methods that utilize these cells. By establishing this foundational framework, the company aspires to contribute to global and sustainable growth in regenerative medicine, femtech, and related fields.

• - Founded: August 5, 1999 (Listed on TSE Growth: 7096)
• - Capital Stock: 707 million JPY
• - CEO: Takafumi Shimizu
• - Head Office: 2nd Floor, Tokyu Toranomon Building, 1-21-19 Toranomon, Minato, Tokyo, 105-0001, Japan
• - Contact: 03-6811-3230 / Official Website
• - Group Companies: STEMCELL INNOVATIONS PTE. LTD. (Singapore), Milch Care Co., Ltd.